Research programme: ZW 34 - ZymeworksAlternative Names: Research programme: ZW-34 - Zymeworks
Latest Information Update: 21 Jul 2016
At a glance
- Originator Zymeworks
- Class Bispecific antibodies; Proteins
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 21 Jul 2016 Zymeworks plans to submit an IND application in Canada in 2016/2017